Ilyang Pharmaceutical Co.,Ltd (KRX: 007570)
South Korea
· Delayed Price · Currency is KRW 10,780
-80 (-0.74%)
Dec 20, 2024, 12:08 PM KST
Ilyang Pharmaceutical Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 364,562 | 370,537 | 383,811 | 371,348 | 343,329 | 324,573 | Upgrade
|
| Other Revenue | 0 | - | - | - | - | 0 | Upgrade
|
| Revenue | 364,562 | 370,537 | 383,811 | 371,348 | 343,329 | 324,573 | Upgrade
|
| Revenue Growth (YoY) | -0.78% | -3.46% | 3.36% | 8.16% | 5.78% | 8.18% | Upgrade
|
| Cost of Revenue | 168,456 | 170,520 | 167,960 | 167,054 | 161,690 | 145,915 | Upgrade
|
| Gross Profit | 196,107 | 200,017 | 215,851 | 204,293 | 181,638 | 178,658 | Upgrade
|
| Selling, General & Admin | 140,628 | 143,179 | 147,306 | 139,430 | 124,701 | 127,549 | Upgrade
|
| Research & Development | 29,615 | 27,439 | 25,960 | 20,196 | 19,723 | 15,850 | Upgrade
|
| Other Operating Expenses | 3,337 | 3,692 | 1,911 | 1,832 | 1,944 | 1,650 | Upgrade
|
| Operating Expenses | 175,553 | 175,204 | 175,444 | 163,268 | 147,538 | 146,147 | Upgrade
|
| Operating Income | 20,553 | 24,813 | 40,408 | 41,025 | 34,101 | 32,511 | Upgrade
|
| Interest Expense | -3,399 | -3,691 | -2,459 | -2,058 | -3,017 | -4,235 | Upgrade
|
| Interest & Investment Income | 684.23 | 390.62 | 1,010 | 938.83 | 516.99 | 340.71 | Upgrade
|
| Earnings From Equity Investments | -14,556 | -16,500 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -315.11 | -1,061 | -283.07 | 952.78 | -918.59 | -214.68 | Upgrade
|
| Other Non Operating Income (Expenses) | -926.16 | -952.36 | 2,696 | -2,197 | -354.03 | -235.48 | Upgrade
|
| EBT Excluding Unusual Items | 2,041 | 2,998 | 41,372 | 38,661 | 30,329 | 28,167 | Upgrade
|
| Gain (Loss) on Sale of Investments | 33.24 | 8.92 | -24.78 | - | -123.55 | 0.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.03 | 0.53 | 21.22 | -26.46 | 134.47 | -506.76 | Upgrade
|
| Asset Writedown | -25.95 | 40.51 | -36.82 | 292.5 | -1,947 | - | Upgrade
|
| Pretax Income | 2,050 | 3,048 | 41,331 | 38,927 | 28,393 | 27,661 | Upgrade
|
| Income Tax Expense | -124.62 | 2,936 | 9,590 | 12,972 | 6,847 | 8,066 | Upgrade
|
| Earnings From Continuing Operations | 2,174 | 111.71 | 31,741 | 25,956 | 21,545 | 19,595 | Upgrade
|
| Minority Interest in Earnings | -2,991 | -2,658 | -12,503 | -11,572 | -10,666 | -9,610 | Upgrade
|
| Net Income | -816.76 | -2,546 | 19,238 | 14,384 | 10,880 | 9,985 | Upgrade
|
| Preferred Dividends & Other Adjustments | -79.09 | -79.09 | 449.28 | - | - | - | Upgrade
|
| Net Income to Common | -737.67 | -2,467 | 18,789 | 14,384 | 10,880 | 9,985 | Upgrade
|
| Net Income Growth | - | - | 33.75% | 32.21% | 8.96% | - | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | -0.42% | -0.59% | -0.44% | - | - | -0.29% | Upgrade
|
| EPS (Basic) | -41.05 | -136.91 | 1036.59 | 790.09 | 597.61 | 548.47 | Upgrade
|
| EPS (Diluted) | -44.30 | -140.00 | 1036.00 | 790.00 | 597.00 | 548.00 | Upgrade
|
| EPS Growth | - | - | 31.14% | 32.33% | 8.94% | - | Upgrade
|
| Free Cash Flow | -24,100 | 13,293 | 25,854 | 54,109 | 47,310 | 34,019 | Upgrade
|
| Free Cash Flow Per Share | -1340.98 | 737.75 | 1426.40 | 2972.19 | 2598.70 | 1868.64 | Upgrade
|
| Dividend Per Share | 150.000 | 150.000 | - | - | - | - | Upgrade
|
| Gross Margin | 53.79% | 53.98% | 56.24% | 55.01% | 52.91% | 55.04% | Upgrade
|
| Operating Margin | 5.64% | 6.70% | 10.53% | 11.05% | 9.93% | 10.02% | Upgrade
|
| Profit Margin | -0.20% | -0.67% | 4.90% | 3.87% | 3.17% | 3.08% | Upgrade
|
| Free Cash Flow Margin | -6.61% | 3.59% | 6.74% | 14.57% | 13.78% | 10.48% | Upgrade
|
| EBITDA | 32,705 | 38,417 | 53,472 | 53,675 | 46,765 | 42,601 | Upgrade
|
| EBITDA Margin | 8.97% | 10.37% | 13.93% | 14.45% | 13.62% | 13.13% | Upgrade
|
| D&A For EBITDA | 12,152 | 13,604 | 13,065 | 12,650 | 12,664 | 10,090 | Upgrade
|
| EBIT | 20,553 | 24,813 | 40,408 | 41,025 | 34,101 | 32,511 | Upgrade
|
| EBIT Margin | 5.64% | 6.70% | 10.53% | 11.05% | 9.93% | 10.02% | Upgrade
|
| Effective Tax Rate | - | 96.33% | 23.20% | 33.32% | 24.12% | 29.16% | Upgrade
|
| Advertising Expenses | - | 41,240 | 42,422 | 35,105 | 35,608 | 37,098 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.